Deal Size Increased to 21.18M Shares, Priced at Top End of $16.00-$18.00 Range
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy EIKN?
The deal size was increased to 21.18M shares from 17.65M and priced at top end of $16.00-$18.00 range. JPMorgan and Morgan Stanley are acting as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EIKN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EIKN
Wall Street analysts forecast EIKN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EIKN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 14.500
Low
Averages
High
Current: 14.500
Low
Averages
High
No data
About EIKN
Eikon Therapeutics, Inc. is a United States-based drug discovery and development company. The Company’s platform allows resolution microscopy as well as the advances in biology, chemistry, engineering, and automation. It tracks and measures the real-time movement of individual proteins in living cells to understanding of disease biology and discover differentiated therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. IPO Market Set for Significant Wave in 2026
- Surge in IPO Proceeds: Goldman Sachs projects that U.S. IPO proceeds will reach a record $160 billion in 2026, quadrupling from 2025, indicating strong economic recovery and robust equity markets.
- Doubling of IPO Count: The number of IPOs is expected to double to 120 in 2026, driven by a recovering economy, rising equity prices, and favorable financial conditions, with software and healthcare sectors leading the charge.
- Large Company Listings: Goldman Sachs notes that 2026 IPOs will be dominated by large private company listings, with proceeds estimated between $80 billion and $200 billion, although recent selloffs in software stocks highlight valuation risks.
- Signs of Market Activity: Approximately $5 billion has already been raised through IPOs in 2026, including notable companies like AI equipment manufacturer Forgent Power and biopharmaceutical firm Eikon Therapeutics, reflecting a strong market rebound.
See More
US IPO Market Set for Major Rebound in 2026
- IPO Revenue Forecast: Goldman Sachs analysts predict that US IPO proceeds will reach a record $160 billion in 2026, quadrupling from 2025, reflecting strong demand for major companies, particularly with anticipated listings from SpaceX and OpenAI.
- Surge in IPO Numbers: The number of IPOs is expected to double to 120 in 2026, driven by economic growth, rising equity prices, and improved financial conditions, indicating strong market interest and confidence in new public offerings.
- Industry Dominance: Software and healthcare firms are set to dominate the IPO pipeline by volume, while late-stage tech and AI companies are expected to drive proceeds, showcasing ongoing investor focus and trust in technological innovation.
- Market Risk Warning: Despite the optimistic outlook, Goldman warns that ongoing volatility in software stocks and lack of corporate confidence could impact the IPO market, particularly as the software sector accounts for about a quarter of the IPO backlog, necessitating close monitoring of market dynamics.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
Amazon Takes Bold Steps in AI Investment, Posing Significant Risks for Markets.
Amazon's Spending Forecast: Amazon's recent spending forecast has surprised the markets, contrasting sharply with the prevailing risk-averse sentiment among investors.
Concerns Over AI Investments: This situation raises concerns about whether the current enthusiasm for artificial intelligence investments may mirror the speculative excesses seen during the dot-com bubble.
See More
Liftoff Mobile Delays IPO Plans for the Time Being
- IPO Postponement: Liftoff Mobile has delayed its initial public offering (IPO) due to unfavorable market conditions.
- Market Impact: The decision follows a day marked by significant declines in stock prices.
See More
Eikon Therapeutics Raises $381 Million in Upsized IPO
- Expanded Financing: Eikon Therapeutics successfully raised $381 million in its IPO by offering 21.2 million shares at $18 each, exceeding its original plan of 17.6 million shares, indicating strong market demand for its immuno-responsive cancer therapies.
- Listing Plans: The company intends to list on Nasdaq under the ticker EIKN, and this successful IPO will provide substantial funding for its ongoing research and development, facilitating further growth in the biotechnology sector.
- Strong Underwriting Team: J.P. Morgan, Morgan Stanley, BofA Securities, Cantor Fitzgerald, and Mizuho Securities acted as joint bookrunners for the deal, showcasing their influence and expertise in the capital markets.
- Positive Market Reaction: The success of this IPO not only reflects investor confidence in Eikon Therapeutics' future growth potential but also sends a positive signal to other biotech companies, potentially stimulating more IPO activities in the sector.
See More
U.S. IPO Market Set for Significant Wave in 2026
- Surge in IPO Proceeds: Goldman Sachs projects that U.S. IPO proceeds will reach a record $160 billion in 2026, quadrupling from 2025, indicating strong economic recovery and robust equity markets.
- Doubling of IPO Count: The number of IPOs is expected to double to 120 in 2026, driven by a recovering economy, rising equity prices, and favorable financial conditions, with software and healthcare sectors leading the charge.
- Large Company Listings: Goldman Sachs notes that 2026 IPOs will be dominated by large private company listings, with proceeds estimated between $80 billion and $200 billion, although recent selloffs in software stocks highlight valuation risks.
- Signs of Market Activity: Approximately $5 billion has already been raised through IPOs in 2026, including notable companies like AI equipment manufacturer Forgent Power and biopharmaceutical firm Eikon Therapeutics, reflecting a strong market rebound.
See More
US IPO Market Set for Major Rebound in 2026
- IPO Revenue Forecast: Goldman Sachs analysts predict that US IPO proceeds will reach a record $160 billion in 2026, quadrupling from 2025, reflecting strong demand for major companies, particularly with anticipated listings from SpaceX and OpenAI.
- Surge in IPO Numbers: The number of IPOs is expected to double to 120 in 2026, driven by economic growth, rising equity prices, and improved financial conditions, indicating strong market interest and confidence in new public offerings.
- Industry Dominance: Software and healthcare firms are set to dominate the IPO pipeline by volume, while late-stage tech and AI companies are expected to drive proceeds, showcasing ongoing investor focus and trust in technological innovation.
- Market Risk Warning: Despite the optimistic outlook, Goldman warns that ongoing volatility in software stocks and lack of corporate confidence could impact the IPO market, particularly as the software sector accounts for about a quarter of the IPO backlog, necessitating close monitoring of market dynamics.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
Amazon Takes Bold Steps in AI Investment, Posing Significant Risks for Markets.
Amazon's Spending Forecast: Amazon's recent spending forecast has surprised the markets, contrasting sharply with the prevailing risk-averse sentiment among investors.
Concerns Over AI Investments: This situation raises concerns about whether the current enthusiasm for artificial intelligence investments may mirror the speculative excesses seen during the dot-com bubble.
See More
Liftoff Mobile Delays IPO Plans for the Time Being
- IPO Postponement: Liftoff Mobile has delayed its initial public offering (IPO) due to unfavorable market conditions.
- Market Impact: The decision follows a day marked by significant declines in stock prices.
See More
Eikon Therapeutics Raises $381 Million in Upsized IPO
- Expanded Financing: Eikon Therapeutics successfully raised $381 million in its IPO by offering 21.2 million shares at $18 each, exceeding its original plan of 17.6 million shares, indicating strong market demand for its immuno-responsive cancer therapies.
- Listing Plans: The company intends to list on Nasdaq under the ticker EIKN, and this successful IPO will provide substantial funding for its ongoing research and development, facilitating further growth in the biotechnology sector.
- Strong Underwriting Team: J.P. Morgan, Morgan Stanley, BofA Securities, Cantor Fitzgerald, and Mizuho Securities acted as joint bookrunners for the deal, showcasing their influence and expertise in the capital markets.
- Positive Market Reaction: The success of this IPO not only reflects investor confidence in Eikon Therapeutics' future growth potential but also sends a positive signal to other biotech companies, potentially stimulating more IPO activities in the sector.
See More
